Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doris K Hansen

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Blood|April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR AnalysisSurbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood Advances|June 12, 2023
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myelomaDae Hyun Lee, Abhishek Kumar, Turab Mohammed, et al.
Blood Cancer Journal|April 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR studyDoris K Hansen, Danai Dima, Hira Mian, et al.
Blood|July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple MyelomaHitomi Hosoya, Arash Velayati, Danai Dima, et al.
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Transplantation and Cellular Therapy|June 16, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall SurvivalGurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Blood|April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR AnalysisSurbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood Advances|June 12, 2023
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myelomaDae Hyun Lee, Abhishek Kumar, Turab Mohammed, et al.
Blood Cancer Journal|April 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR studyDoris K Hansen, Danai Dima, Hira Mian, et al.
Blood|July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple MyelomaHitomi Hosoya, Arash Velayati, Danai Dima, et al.
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Transplantation and Cellular Therapy|June 16, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall SurvivalGurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Pageof 8